Karyopharm Therapeutics is a commercial-stage pharmaceutical company that develops and commercializes drugs to treat cancer and other diseases. They've discovered selective inhibitor of nuclear export (SINE) compounds that bind and inhibit the nuclear export protein XPO1 leading to the treatment of adult patients with multiple myeloma and refractory diffuse large B-cell lymphoma. Karyopharm has a license agreement with Menarini Group to develop and commercialize NEXPOVIO for human oncology indications in Europe, Latin America, and other countries.